Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

netupitant Articles

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16 May 2013

Helsinn out-licenses netupitant-palonosetron fixed dose combo in South Korea

25 September 2012

Helsinn moving forward with supportive cancer care products anamorelin and netupitant + palonosetron

26 September 2011

Helsinn and Taiho Pharma to extend relationship with CINV drug accord

14 April 2011

Helsinn Healthcare and Eisai extend relationship, including US Aloxi marketing

10 June 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS